619 completed. 619 Phase 2, 121 Phase 1, 48 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 619 | Completed 619 |
| Phase 1 | 121 | Completed 121 |
| Phase 3 | 48 | Completed 48 |
Follow Congenital Abnormalities: new trials by email Literature Review of Congenital Abnormalities trials Research Report on Congenital Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic IV Paracetamol in Extremely Premature Infants Paracetamol (drug) - Patent Ductus Arteriosus in Preterm Infants, Patent Ductus Arteriosus After Premature Birth | Phase 2 / Phase 3 | Completed | Al-Quds University | 40 | 2025-01-01 | 2026-04-07 |
| Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) Tuvusertib (M1774), Niraparib, Lartesertib (M4076) - Ovarian Cancer | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 63 | 2024-10-30 | 2026-09-14 |
| PK/PD of Digoxin in Infants With SVHD PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease - Single-ventricle, Infant Conditions | Phase 1 / Phase 2 | Completed | Duke University | 24 | 2024-10-10 | 2026-08-14 |
| Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease NMD670, Placebo - Charcot-Marie-Tooth Disease | Phase 2 | Completed | NMD Pharma A/S | 81 | 2024-09-30 | 2025-11-12 |
| Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease Empagliflozin, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Cantonal Hospital Graubuenden | 16 | 2024-09-01 | 2026-09-22 |
| Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) Vonafexor - Alport Syndrome | Phase 2 | Completed | Enyo Pharma | 26 | 2024-08-01 | 2026-02-09 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Bivamelagon, Placebo - Hypothalamic Obesity | Phase 2 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-07-11 | 2026-10-30 |
| Study of SPG601 in Adult Men With Fragile X Syndrome SPG601, Placebo - Fragile X Syndrome | Phase 2 | Completed | Spinogenix | 10 | 2024-07-05 | 2026-05-26 |
| Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy Trimetazidine, Placebo - Peripheral Neuropathy Due to Chemotherapy | Phase 1 / Phase 2 | Completed | Minia University | 60 | 2024-06-23 | 2025-03-30 |
| Comparison of Rimegepant and Placebo for Pain in IBS Rimegepant 75 MG [Nurtec] - Irritable Bowel Syndrome | Phase 2 | Completed | Mayo Clinic | 39 | 2024-06-06 | 2026-10-15 |
| The Desensitising Effect of Nanosilver Fluoride in Molar-Incisor Hypomineralisation Low-level laser therapy, Nanosilver fluoride - Molar Incisor Hypomineralization, Hypersensitivity | Phase 2 / Phase 3 | Completed | Alexandria University | 120 | 2024-04-01 | 2025-01-30 |
| IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy IC14 - Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy | Phase 1 / Phase 2 | Completed | Implicit Bioscience | 1 | 2024-03-29 | 2026-04-22 |
| Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome Clemastine Fumarate Tablets, corn starch tablets - Williams Syndrome, Child | Phase 2 | Completed | Qilu Hospital of Shandong University | 28 | 2024-03-20 | 2026-03-19 |
| A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses deucravacitinib - Epidermolysis Bullosa Simplex, Ichthyosis | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2024-03-18 | 2026-10-16 |
| Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS) Gaboxadol, Placebo - Fragile X Syndrome | Phase 2 | Completed | Craig Erickson | 10 | 2024-01-29 | 2026-09-30 |
| A Study to Evaluate Setanaxib in Patients With Alport Syndrome Setanaxib, Placebo - Alport Syndrome | Phase 1 / Phase 2 | Completed | Calliditas Therapeutics AB | 20 | 2023-11-27 | 2026-04-13 |
| Augmented Reality for Orthognatic Surgery Patient Education Patient consultation - Malocclusion, Dentofacial Deformities | Phase 2 / Phase 3 | Completed | University Medical Center Groningen | 60 | 2023-10-01 | 2025-03-30 |
| Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) M1774, Cemiplimab - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 61 | 2023-09-13 | 2026-09-14 |
| A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. Alogabat - Angelman Syndrome | Phase 2 | Completed | Hoffmann-La Roche | 48 | 2023-07-27 | 2025-12-04 |
| Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography. Ketamine, Midazolam, Pethidin - Cholangitis, Pancreatic Cancer | Phase 2 | Completed | National University of Malaysia | 90 | 2023-07-18 | 2025-03-25 |
Showing 20 of 619. Sign in to see all of them.
Leukemia, Myeloid, Acute (110) · Leukemia (71) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (57) · Myeloproliferative Disorders (52) · Myelodysplastic Syndromes (50) · Leukemia, Lymphocytic, Chronic, B-Cell (49) · Leukemia, Myeloid, Accelerated Phase (48) · Leukemia, Myeloid, Chronic-Phase (48) · Lymphoma, Follicular (48) · Lymphoma, Non-Hodgkin (46) · Lymphoma, Large B-Cell, Diffuse (45) · Leukemia, Myelomonocytic, Chronic (44) · Burkitt Lymphoma (43) · Hodgkin Disease (42)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (619) · Genetic Diseases, Inborn (295) · Neoplasms (198) · Cardiovascular Diseases (190) · Pathological Conditions, Signs and Symptoms (190) · Hemic and Lymphatic Diseases (179) · Neoplasms by Histologic Type (177) · Nervous System Diseases (176) · Hematologic Diseases (163) · Abnormalities, Multiple (137) · Pathologic Processes (133) · Cardiovascular Abnormalities (126) · Leukemia, Myeloid (119) · Bone Marrow Diseases (110)
fludarabine phosphate (40) · Busulfan (38) · Cyclophosphamide (36) · Peripheral Blood Stem Cell Transplantation (33) · Cytarabine (31) · Tacrolimus (31) · Mycophenolic Acid (27) · Methotrexate (26) · Antilymphocyte Serum (25) · Cyclosporine (24) · Whole-Body Irradiation (22) · Sirolimus (19) · Etoposide (17) · Filgrastim (15) · Radiotherapy (14)
Fred Hutchinson Cancer Center (27) · National Cancer Institute (NCI) (25) · Case Comprehensive Cancer Center (11) · Novartis Pharmaceuticals (10) · Mirum Pharmaceuticals, Inc. (7) · Stanford University (7) · Children's Hospital Medical Center, Cincinnati (6) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (6) · Mayo Clinic (6) · Memorial Sloan Kettering Cancer Center (6) · University Hospital, Toulouse (6) · Hoffmann-La Roche (5) · Hospices Civils de Lyon (5) · Incyte Corporation (5) · Masonic Cancer Center, University of Minnesota (5)
United States (426) · France (69) · Canada (47) · Italy (47) · Spain (45) · United Kingdom (41) · Germany (39) · Australia (27) · Belgium (21) · Netherlands (19) · Israel (18) · South Korea (17) · China (16) · Switzerland (14) · Denmark (13)
Ervin Epstein, MD (5) · Judith Karp (5) · Elizabeth Berry-Kravis, MD, PhD (4) · Anthony S. Stein, MD (3) · Asad Bashey, MD, PhD (3) · Brenda Sandmaier (3) · David Meeker, MD (3) · Jakub Tolar, MD, PhD (3) · John Pagel (3) · Kyoo H. Lee, MD (3) · M. Louise Markert, MD, PhD (3) · Marie E Faughnan, MD MSc FRCPC (3)
PMID 39356039, PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 32499241, PMID 40938675, PMID 42002216, PMID 17284531, PMID 21903984, PMID 26764156, PMID 31541747, PMID 34146101, PMID 36519620, PMID 37250503, PMID 38837240, PMID 12702512, PMID 14605787, PMID 14662594, PMID 17146105, PMID 17662768, PMID 17763894, PMID 17910637, PMID 18155964, PMID 18184959, PMID 18195173, PMID 18245545, PMID 18327587, PMID 18513295, PMID 18769450, PMID 18812735, PMID 19117316, PMID 19179301, PMID 19286996, PMID 19638218, PMID 19794082, PMID 19841031, PMID 19900571, PMID 19909499, PMID 19912236, PMID 20008831, PMID 20083693, PMID 20084109, PMID 20124511, PMID 20368434, PMID 20383216, PMID 20443823, PMID 20674758, PMID 20691689
P30CA015704 (12), P30CA043703 (9), 2017 (8), P30CA006973 (7), U01CA070095 (7), 2015 (5), 2019 (5), U10CA032102 (5), P30CA033572 (4), 2009 (3), 2018 (3), K12HD043494 (3), P01CA018029 (3), R01AI047040 (3), R01AI054843 (3)